|
|
Minimally invasive image-guided tumor ablation in an oncogenic pig model
|
1R21CA195433-01A1
|
$225,795
|
$225,795
|
BURDETTE, EVERETTE
|
ACOUSTIC MEDSYSTEMS, INC.
|
|
|
Novel Ras inhibitor prodrug for colorectal cancer
|
1R43CA206807-01
|
$300,000
|
$300,000
|
CANZONERI, JOSHUA
|
ADT PHARMACEUTICALS, INC.
|
|
|
Immuno-Oncology for Pancreatic Cancer: A Combination Clinical Trial with Chemotherapy and Radiation
|
1R44CA203336-01
|
$299,985
|
$299,985
|
AGUILAR-CORDOVA, ESTUARDO
|
ADVANTAGENE, INC
|
|
|
2/2 The Alabama State University/UAB Comprehensive Cancer Center Partnership
|
3P20CA192976-02S1
|
$20,000
|
$10,600
|
MISHRA, MANOJ
|
ALABAMA STATE UNIVERSITY
|
|
|
2/2 The Alabama State University/UAB Comprehensive Cancer Center Partnership
|
5P20CA192976-03
|
$144,556
|
$76,615
|
MISHRA, MANOJ
|
ALABAMA STATE UNIVERSITY
|
|
|
OPTION PERIOD 1: PATIENT ACCRUAL AND TREATMENT 12/30/2015-12/29/2016
|
261201500022C
|
$445,512
|
$445,512
|
UNKNOWN, UNKNOWN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
|
Novel Strategies for Precision T-cell Therapies
|
1R01CA198095-01A1
|
$520,564
|
$520,564
|
ALMO, STEVEN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Age and Diet: Major interacting factors that drive sporadic intestinal cancer
|
5R01CA174432-04
|
$660,173
|
$660,173
|
AUGENLICHT, LEONARD
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
DNA Mismatch repair and cancer in murine models
|
5R01CA076329-20
|
$380,585
|
$380,585
|
EDELMANN, WINFRIED
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Small Molecule Activators of Pro-apoptotic BAX for Cancer Therapy
|
5R01CA178394-03
|
$346,525
|
$173,263
|
GAVATHIOTIS, EVRIPIDIS
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Core Support for Cancer Center
|
3P30CA013330-44S1
|
$199,871
|
$47,969
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Core Support for Cancer Center
|
3P30CA013330-44S2
|
$199,989
|
$47,997
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Core Support for Cancer Center
|
3P30CA013330-44S3
|
$500,000
|
$120,000
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Core Support for Cancer Center
|
5P30CA013330-44
|
$3,746,138
|
$899,073
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Treating pancreatic cancer with Listeria-32P
|
5R21CA199010-03
|
$181,613
|
$181,613
|
GRAVEKAMP, CLAUDIA
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Deciphering the Tissue Specificity of MEN1 Related Tumorigenesis
|
5R01CA170911-06
|
$346,525
|
$173,263
|
LIBUTTI, STEVEN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Development of Novel Drugs to Alleviate CPT-11 Toxicity
|
5R01CA161879-06
|
$325,379
|
$325,379
|
MANI, SRIDHAR
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Par1-substrates responsible for CagA-mediated pathogenesis of Helicobacter pylori
|
5R01CA160790-06
|
$522,889
|
$522,889
|
MUESCH, ANNE
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Tumor expressed B7x accelerates disease and is a novel target for immunotherapy
|
5F31CA183493-03
|
$48,576
|
$24,288
|
OHAEGBULAM, KIM
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Interactions of the angiopoietin and PD-ECGF pathways in tumor angiogenesis
|
5R01CA163907-06
|
$346,525
|
$346,525
|
SCHWARTZ, EDWARD
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
The B7x pathway in the tumor microenvironment
|
5R01CA175495-04
|
$346,525
|
$138,610
|
ZANG, XINGXING
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Colon cancer risk-stratification via optical analysis of rectal ultrastructure
|
1R44CA199667-01A1
|
$1,030,462
|
$1,030,462
|
WALI, RAMESH
|
AMERICAN BIOOPTICS, LLC
|
|
|
Exploiting the immune response to detect pathogen-induced cancers
|
5R01CA199948-02
|
$496,815
|
$496,815
|
LABAER, JOSHUA
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
|
Multiplexed In Solution Protein Array (MISPA) for identifying novel protein interactions in cancer and for early detection of immune responses in pathogen-induced cancers
|
5R21CA196442-02
|
$235,226
|
$235,226
|
LABAER, JOSHUA
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
|
Couple Communication in Cancer: A Multi-Method Examination
|
1R01CA201179-01A1
|
$693,817
|
$346,909
|
LANGER, SHELBY
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
|
Navigation from Community to Clinic to promote CRC Screening in Underserved Popul
|
4R01CA162393-05
|
$538,307
|
$538,307
|
LARKEY, LINDA
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
|
Modeling Neoplastic Progression in Barrett's Esophagus
|
5R01CA140657-08
|
$357,493
|
$357,493
|
MALEY, CARLO
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
|
Highly specific ATR inhibitors for the targeted treatment of a broad spectrum of cancers
|
1R41CA203436-01A1
|
$299,998
|
$149,999
|
BROWN, ERIC
|
ATRIN PHARMACEUTICALS
|
|
|
Development of cell-free DNA assays for HCC screening and liquid biopsy
|
1R01CA202769-01
|
$432,900
|
$432,900
|
SU, YING-HSIU
|
BARUCH S. BLUMBERG INSTITUTE
|
|
|
PNNL Proteome Characterization Center
|
1U24CA210955-01
|
$1,123,778
|
$382,085
|
LIU, TAO
|
BATTELLE PACIFIC NORTHWEST LABORATORIES
|
|
|
High Resolution Microendoscopy for the Management of Esophageal Neoplasia
|
5R01CA181275-03
|
$587,321
|
$587,321
|
ANANDASABAPATHY, SHARMILA
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
A New Lab Based Algorithm for HCC Surveillance in Patients with Cirrhosis
|
5R01CA190776-02
|
$636,299
|
$636,299
|
EL-SERAG, HASHEM
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Enhancing T Cell Therapy of Cancer
|
4P01CA094237-14
|
$1,932,287
|
$483,072
|
HESLOP, HELEN
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Novel targets that are deregulated by loss of PTEN
|
5R01CA108614-10
|
$288,103
|
$288,103
|
JOHNSON, DEBORAH
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
TRANSCRIPTION FACTORS IN INTESTINAL DIFFERENTIATION AND CANCER
|
1F99CA212433-01
|
$45,076
|
$45,076
|
LO, YUAN-HUNG
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-10S1
|
$118,016
|
$18,883
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-10S2
|
$170,897
|
$27,344
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-10S3
|
$118,875
|
$19,020
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-10S4
|
$499,947
|
$79,992
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-10S5
|
$134,220
|
$21,475
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
5P30CA125123-10
|
$3,253,119
|
$520,499
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Gut L-Histidine Metabolism and Histamine Signaling in Colonic Neoplasia
|
4U01CA170930-04
|
$565,491
|
$565,491
|
VERSALOVIC, JAMES
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
A novel miR-198 replacement therapy for pancreatic cancer
|
5R01CA183984-02
|
$473,915
|
$473,915
|
YAO, QIZHI
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
iPGDAC, An Integrative Proteogenomic Data Analysis Center for CPTAC
|
1U24CA210954-01
|
$1,004,827
|
$331,593
|
ZHANG, BING
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
MicroRNA Biomarkers for Determining Treatment Response in Colorectal Cancer
|
1R01CA202797-01A1
|
$360,913
|
$360,913
|
GOEL, AJAY
|
BAYLOR RESEARCH INSTITUTE
|
|
|
Familial and Early Onset Colorectal Cancer
|
5R01CA072851-20
|
$372,400
|
$372,400
|
GOEL, AJAY
|
BAYLOR RESEARCH INSTITUTE
|
|
|
METHYLATION BIOMARKER DEVELOPMENT FOR NONINVASIVE DETECTION OF COLORECTAL CANCER
|
5R01CA181572-03
|
$315,983
|
$315,983
|
GOEL, AJAY
|
BAYLOR RESEARCH INSTITUTE
|
|
|
Development of microRNA Biomarkers For Noninvasive Detection of Colorectal Cancer
|
5R01CA184792-02
|
$359,828
|
$359,828
|
GOEL, AJAY
|
BAYLOR RESEARCH INSTITUTE
|
|
|
Aspirin and Cancer Prevention in Lynch Syndrome: From Cell to Population Data
|
5U01CA187956-03
|
$555,997
|
$555,997
|
GOEL, AJAY
|
BAYLOR RESEARCH INSTITUTE
|
|
|
Cancer Center Support Grant
|
3P30CA033572-33S1
|
$125,651
|
$1,257
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Total relevant funding to Digestive Diseases for this search: $502,916,313
|
